MedTrace Logo

Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program

NCT05878119 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2026-01-21

No results posted yet for this study

Summary

A single-center, randomized, placebo-controlled study in community dwelling, healthy, regularly exercising, highly physically fit men and women, 19 to 40 years. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily for 10 weeks.

Conditions

  • Healthy

Interventions

DRUG

Investigational Product - MIB 626

The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.

DRUG

Placebo

Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC

OTHER

Standardized, progressive, high intensity, multidimensional exercise

Participants will be asked to perform high intensity, standardized, progressive, multidimensional exercise.

OTHER

Usual Physical Activity

Participants will be asked to perform usual physical activity per listed in the protocol

Sponsors & Collaborators

  • Metro International Biotech, LLC

    lead INDUSTRY

Principal Investigators

  • Shalender Bhasin, MD · Brigham and Women's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-25
Primary Completion
2025-06-17
Completion
2025-08-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05878119 on ClinicalTrials.gov